Testing must also be done to ensure there are no rearrangements involving platelet‐derived growth factor A (PDGFRA), PDGFRB, fibroblast growth factor receptor 1 (FGFR1), or pericentriolar material 1 (PCM1)‐Janus kinase 2 (JAK2) fusions in patients with eosinophilia to exclude this group of myeloid neoplasms [1]. Here, FGFR1 is linked to myeloid neoplasm.